Compare AJANTA PHARMA with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TORRENT PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA TORRENT PHARMA AJANTA PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 20.4 36.0 56.6% View Chart
P/BV x 4.8 7.5 64.5% View Chart
Dividend Yield % 0.6 1.4 41.4%  

Financials

 AJANTA PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-21
TORRENT PHARMA
Mar-21
AJANTA PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,8833,040 61.9%   
Low Rs1,2581,933 65.1%   
Sales per share (Unadj.) Rs334.0473.0 70.6%  
Earnings per share (Unadj.) Rs75.674.0 102.1%  
Cash flow per share (Unadj.) Rs89.0112.9 78.8%  
Dividends per share (Unadj.) Rs9.5035.00 27.1%  
Avg Dividend yield %0.61.4 43.0%  
Book value per share (Unadj.) Rs346.1344.9 100.3%  
Shares outstanding (eoy) m86.53169.22 51.1%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x4.75.3 89.5%   
Avg P/E ratio x20.833.6 61.8%  
P/CF ratio (eoy) x17.722.0 80.1%  
Price / Book Value ratio x4.57.2 62.9%  
Dividend payout %12.647.3 26.6%   
Avg Mkt Cap Rs m135,898420,798 32.3%   
No. of employees `000NANA-   
Total wages/salary Rs m5,48314,396 38.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m28,89780,048 36.1%  
Other income Rs m260757 34.3%   
Total revenues Rs m29,15780,806 36.1%   
Gross profit Rs m9,98624,666 40.5%  
Depreciation Rs m1,1616,578 17.6%   
Interest Rs m833,583 2.3%   
Profit before tax Rs m9,00215,263 59.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4632,744 89.8%   
Profit after tax Rs m6,53912,519 52.2%  
Gross profit margin %34.630.8 112.1%  
Effective tax rate %27.418.0 152.2%   
Net profit margin %22.615.6 144.7%  
BALANCE SHEET DATA
Current assets Rs m22,17855,232 40.2%   
Current liabilities Rs m8,38848,916 17.1%   
Net working cap to sales %47.77.9 604.8%  
Current ratio x2.61.1 234.2%  
Inventory Days Days5314 367.5%  
Debtors Days Days97 134.3%  
Net fixed assets Rs m18,91281,298 23.3%   
Share capital Rs m174846 20.6%   
"Free" reserves Rs m29,77757,526 51.8%   
Net worth Rs m29,95158,372 51.3%   
Long term debt Rs m1629,633 0.1%   
Total assets Rs m41,090136,530 30.1%  
Interest coverage x109.85.3 2,088.4%   
Debt to equity ratio x00.5 0.1%  
Sales to assets ratio x0.70.6 119.9%   
Return on assets %16.111.8 136.6%  
Return on equity %21.821.4 101.8%  
Return on capital %30.321.4 141.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m18,09721,539 84.0%   
Fx outflow Rs m2,3157,136 32.4%   
Net fx Rs m15,78214,403 109.6%   
CASH FLOW
From Operations Rs m5,76320,107 28.7%  
From Investments Rs m-2,824-4,494 62.8%  
From Financial Activity Rs m-3,183-16,561 19.2%  
Net Cashflow Rs m-244-893 27.3%  

Share Holding

Indian Promoters % 70.5 71.3 98.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 21.4 20.6 103.7%  
FIIs % 8.6 10.9 79.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.5 28.8 102.7%  
Shareholders   60,759 63,229 96.1%  
Pledged promoter(s) holding % 16.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 236 Points Lower, Nifty Falls Below 16,150; IT & FMCG Stocks Witness Selling(Closing)

Indian share markets ended on a negative note today as global cues remained weak.

Related Views on News

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 24, 2022 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS